Biotech Values

[rkrw]

No position? :) CR is certainly impressive. But moving onto a phase 2 study. Big deal. Standards of care in pancreatic may be a moving target in the next few years so it could turn out to be a little late to the game. They'll probably need to do a fund raise before year end so their cash levels don't get to desperate levels next year. If you like it you may as well hold off and invest directly in the PIPE and pickup big warrant coverage.